While Medtronic has struggled to keep up with the broader market over the past year, analysts remain fairly upbeat on its ...

Medtronic's separation of its Medtronic Diabetes unit into a publicly traded company named MiniMed will be a new beginning ...

Medtronic Diabetes today offered a sneak peek at the new Abbott sensor technology specifically designed for its MiniMed ...

As Medtronic advances its SmartGuard™ algorithm towards a fully closed loop system, the company is evaluating the use of its MiniMed 780G system integrated with its proprietary Klue smartwatch ...

The CE mark also allows Medtronic’s automated insulin delivery system to be used during pregnancy and by children as young as two.

About the MiniMed 780G system The MiniMed 780G system is the most advanced insulin pump system from Medtronic, currently approved for the treatment of type 1 diabetes in people aged 7 to 80 years.

Medtronic's introduction of the MiniMed 780G continuous glucose monitoring system and acquisition of EOFlow Co. Ltd. could inspire growth, but will be subject to fierce competition.

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users PR Newswire - Fri Jun 23, 2023 ...

FDA Approves Medtronic MiniMed™ 780G System - World's First Insulin Pump with Meal Detection Technology* Featuring 5-Minute Auto Corrections†§ ...

Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as ...

DUBLIN and SAN DIEGO, June 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the ...

The MiniMed™ 780G system is approved in the U.S. for individuals with type 1 diabetes, 7 years and above. About Medtronic Bold thinking. Bolder actions. We are Medtronic.